Compare · CELL vs VLON
CELL vs VLON
Side-by-side comparison of PhenomeX Inc. (CELL) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELL and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- VLON has more recent analyst coverage (1 ratings vs 0 for CELL).
- Company
- PhenomeX Inc.
- Vallon Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 1
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Latest CELL
- PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform
- PhenomeX Announces The Release Of SpotLight Human Lambda Reagent For The Beacon Platform To Accelerate Cell Line Development Workflows
- PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows
- PhenomeX to Participate in Upcoming Cell Biology Conferences
- PhenomeX Unveils Meteor Chips For Quantitative Bulk Analysis On The IsoSpark Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomic
- PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics
- PhenomeX Inc. Announces Commencement of Cash Tender Offer by Bruker
- Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
- Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL
- Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Latest VLON
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.
- SEC Form EFFECT filed by Vallon Pharmaceuticals Inc.
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders